
|Videos|June 17, 2016
Fulvestrant Plus Palbociclib in Breast Cancer
Author(s)Joanne Blum, MD, PhD, FACP
Joanne Blum, MD, PhD, FACP, physician, Texas Oncology, discusses the combination of fulvestrant and palbociclib (Ibrance) in patients with breast cancer, as well as the synergy fulvestrant has with other CDK4/6 inhibitors.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
2
Early Relapse Guides Use of CAR T vs Other Options in LBCL
3
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
4
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
5








































